Please ensure Javascript is enabled for purposes of website accessibility

Is Mind Medicine a Buy?

By David Jagielski - Jun 17, 2021 at 6:11AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now?

The market for psychedelic drugs could be worth $10.8 billion by 2027, growing at an annual rate of 12.4% until then, according to It's an exciting new sector to invest in, with many people comparing it to the early days of the cannabis industry, and Mind Medicine (MNMD -0.21%) is one investable company at the forefront.

The biotech, also known as MindMed, is in early stages of working on multiple drugs that could potentially hit the psychedelics market. But with no revenue, mounting losses, and a ton of risk, should investors take a chance on the stock?

Two scientists working in a lab.

Image source: Getty Images.

The opportunities are massive

MindMed is developing drugs that can treat many different areas, including depression, addiction, ADHD, and anxiety. And those are some big markets to tap into. The depression drug industry alone is worth an estimated $9.6 billion, followed closely by the ADHD market at $9.5 billion. Anti-addiction medication is a $5.8 billion industry and the anti-anxiety market is worth $4.7 billion.

Currently, the company has multiple clinical trials under way, including its LSD experimental therapy, Project Lucy, which is entering phase 2b trials. It is also entering phase 2 trials for LSD microdosing (Project Flow) and a drug for opioid withdrawal (Project Layla). Last month, MindMed also announced the start of Project Angie, which will look at how effective psychedelics, specifically LSD, are in treating pain.

The company is also working on developing patents and intellectual property. One such example is an LSD neutralizer which aims to stop the hallucinogenic effects of the substance in under 30 minutes. This can help improve the experience for patients while focusing on the medical benefits, not unlike the medical marijuana market where the focus is on wellness rather than achieving a high. 

Patience is a requirement for any serious investor

For a company that doesn't generate any revenue, investors need to be prepared to wait years before there's even any hope of profitability. In 2020, Mind Medicine reported total expenses and losses of more than $35 million. As of March 31, it reported that its cash balance was up to $160 million and that for the quarter it burned through just $10 million to fund its day-to-day operating activities. It's a good sign that the business isn't bleeding too much money and that its cash balance is healthy enough to support its operations. But as the company gets larger and gets deeper into development, both its administrative costs and expenses related to research will likely rise. And so while it may look to be in good shape to fund potentially a year's worth of operations (or more), investors shouldn't assume that to be the case.

Even if it can fund a year or two, that still might not be long enough for the company to start generating revenue to curb the cash bleed. Many of the company's phase 2 trials won't be completed until 2022 or later.

And success in early-stage trials isn't a guarantee that a drug will hit the market. The probability that a drug will pass through all clinical stages successfully and obtain eventual approval is just 20.9% for non-oncology drugs. There is a 66.4% likelihood that they will be able to move from phase 1 to phase 2, but only 48.6% of those drugs will move on to phase 3. And even getting to that stage still doesn't make approval a sure thing, as more than 40% of those drugs will still end up failing. 

Should you take a chance on MindMed

Investing in a company that isn't generating any revenue is always going to be a significant risk. And while it's great that MindMed is working on medicine that could really help people with depression, anxiety, and other conditions, that alone isn't going to mean the company and its drugs will generate any revenue. Without a product it can sell today, the company is going to remain a risky buy and a long shot. Unless you have a high tolerance for risk and are willing to accept the possibility you could lose your entire investment, you should avoid MindMed. While the potential returns could be significant for the stock, so, too, is the risk.

If you want to bet on the psychedelics market, a safer option would be to invest in the Defiance Next Gen Altered Experience ETF. The fund holds MindMed in its portfolio along with other companies from the cannabis and psychedelic industries, enabling you to diversify your overall risk and ensure you aren't putting everything on one very risky stock.

David Jagielski has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Mind Medicine (MindMed) Inc. Stock Quote
Mind Medicine (MindMed) Inc.
$0.65 (-0.21%) $0.00
ETF Series Solutions - Defiance Next Gen Altered Experience ETF Stock Quote
ETF Series Solutions - Defiance Next Gen Altered Experience ETF
$5.92 (0.41%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/11/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.